Impact Of Chronic Hepatitis C Infectionand Liver Metastasis On Survival Outcome Of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer (nsclc) Patient Treated With First-Line Gefetinib In Real-World Practice

被引：0
|
作者：
Yao, Z. -H.
Liao, W. -Y.
Ho, C. -C.
Chen, K. -Y.
Shih, J. -Y.
Chen, J. -S.
Lin, Z. -Z.
Lin, C. -C.
Yang, J. -H.
Yu, C. -J.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2016年 / 193卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4272
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation-positive NSCLC: An interim analysis of the ARIA study
    Wu, L.
    Li, J.
    Xu, C.
    Biswas, B.
    Tang, K.
    Wang, H.
    Liu, Z.
    Batra, U.
    Ho, G. F.
    Low, S. H. J.
    Lu, Y.
    Zhao, M.
    Tho, L. M.
    Zhao, J.
    He, S.
    Huang, J.
    Tang, X.
    Wong, C. H.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2023, 34
  • [42] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
    Park, Keunchil
    Bennouna, Jaafar
    Boyer, Michael
    Hida, Toyoaki
    Hirsh, Vera
    Kato, Terufumi
    Lug, Shun
    Mok, Tony
    Nakagawa, Kazuhiko
    O'Byrne, Kenneth
    Paz-Ares, Luis
    Schuler, Martin
    Sibilotru, Denis Moro
    Tan, Eng-Huat
    Tanaka, Hiroshi
    We, Yi-Long
    Yang, James C-H
    Zhang, Li
    Zhou, Caicun
    Maerten, Angela
    Tang, Wenbo
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 132 : 126 - 131
  • [43] First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
    Takamizawa, Shigemasa
    Okuma, Yusuke
    Kato, Yasuhiro
    Hakozaki, Taiki
    Kitagawa, Shingo
    Zenke, Yoshitaka
    FUTURE ONCOLOGY, 2021, 18 (03) : 291 - 300
  • [44] Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA
    Lim, Jonathan
    Samuelsen, Carl
    Golembesky, Amanda
    Shrestha, Sulena
    Wang, Li
    Griebsch, Ingolf
    FUTURE ONCOLOGY, 2019, 15 (13) : 1493 - 1504
  • [45] Mefatinib as first-line treatment of EGFR sensitizing mutation-positive non-small-cell lung cancer: A phase III efficacy and biomarker study.
    Yu, Jia
    Zhou, Caicun
    Kai, Wang
    Wang, Qiming
    Niu, Hongrui
    Zhou, Cheng-Zhi
    Tian, Panwen
    Zhuang, Wu
    Li, Jie
    Wang, Jing
    Sun, Xu
    Yu, Bing
    Zhu, Chaonan
    Chen, Jianghua
    Xu, June
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data
    Moser, Sarah sharman
    Apter, Lior
    Solomon, Josie
    Chodick, Gabriel
    Wollner, Miriana
    Siegelmann-Danieli, Nava
    ANTICANCER RESEARCH, 2024, 44 (01) : 257 - 265
  • [47] The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study
    Yu, Xiaoqing
    Si, Jinfei
    Wei, Jingwen
    Wang, Yanling
    Sun, Yan
    Jin, Jianan
    Zhang, Xiaoyan
    Ma, Tonghui
    Song, Zhengbo
    CANCER MEDICINE, 2023, 12 (05): : 5630 - 5638
  • [48] Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01)
    Uryu, Kiyoaki
    Imamura, Yoshinori
    Shimoyama, Rai
    Mase, Takahiro
    Fujimura, Yoshiaki
    Hayashi, Maki
    Ohtaki, Megu
    Otani, Keiko
    Hibino, Makoto
    Horiuchi, Shigeto
    Fukui, Tomoya
    Fukai, Ryuta
    Chihara, Yusuke
    Iwase, Akihiko
    Yamada, Noriko
    Tamura, Yukihiro
    Harada, Hiromasa
    Shinozaki, Nobuaki
    Tsuya, Asuka
    Fukuoka, Masahiro
    Minami, Hironobu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (03) : 319 - 328
  • [49] Real-world safety of first-line immuno-oncology combination therapies for advanced non-small-cell lung cancer
    Betts, Keith A.
    Gao, Sophie
    Ray, Saurabh
    Schoenfeld, Adam J.
    FUTURE ONCOLOGY, 2024, 20 (13) : 851 - 862
  • [50] Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
    Takashima, Kenta
    Wakabayashi, Hiroki
    Murakami, Yu
    Saiki, Atsuhito
    Matsuzawa, Yasuo
    DRUGS-REAL WORLD OUTCOMES, 2024, 11 (04) : 603 - 615
12345